Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
17/02/2026 13:38
Feb 17 (Reuters) - Telomir Pharmaceuticals Inc TELO.O: TELOMIR PHARMACEUTICALS INC - DEMONSTRATES BROAD TUMOR CELL MORTALITY IN HUMAN TRIPLE-NEGATIVE BREAST CANCER MODELS TELOMIR PHARMACEUTICALS INC - IRON-RESCUE EXPERIMENTS CONFIRM TUMOR CELL MORTALITY IS MECHANISTICALLY DRIVEN, NOT NONSPECIFIC CYTOTOXICITY TELOMIR PHARMACEUTICALS INC - ANTICIPATES IND APPLICATION SUBMISSION IN Q1 2026 - SEC FILING Source text: [ID:n0001493152-26-006937] Further company coverage: TELO.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Telomir Pharmaceuticals
See all newsBrief: Telomir Pharmaceuticals - Alan Weichselbaum To Step Down As CFO Effective June 6, 2026 - SEC Filing
Brief: Telomir Pharmaceuticals Demonstrates Broad Tumor Cell Mortality In Human Triple-Negative Breast Cancer Models
Brief: Telomir Pharmaceuticals Telomir-1 Significantly Reduced Tumor Growth And Metastases
Brief: Telomir Pharmaceuticals Reports New Data Showing Telomir-1 Resets Cancer’S “Kill-And-Clean” Defense Systems In An Aggressive Prostate Cancer Model
U.S. STOCKS ON THE MOVE-InterDigital, Scholar Rock, Live Nation